@FierceBiotech: Look out, Roche: GlaxoSmithKline aces pivotal studies for pair of melanoma drugs. Story | Follow @FierceBiotech
@JohnCFierce: Updated ASCO roundup story with regorafenib and Aveo study: More | Follow @JohnCFierce
@RyanMFierce: My report on 5 next-gen software tools for biopharma R&D. Report | Follow @RyanMFierce
> Pharmaceutical Research and Manufacturers of America says that American biopharma groups have 981 cancer drugs and vaccines under development or regulatory review. Item
> CytRx ($CYTR) is presenting "favorable" results of its Phase Ib/II clinical trial for the tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors and primary soft tissue sarcomas. Release
> Medistem got the green light continue a clinical trial of a stem cell therapy for congestive heart failure after a safety check of 5 patients who had been treated in the study. Item
> Medivation ($MDVN) and Astellas Pharma touted data from a Phase III study of their experimental drug enzalutamide (formerly MDV3100) in measures of quality of life and time to first skeletal-related event in certain patients with prostate cancer. Release
Pharma News
@FiercePharma: Some non-ASCO news: If Greece leaves euro, drug pricing across EU would get even worse, EFPIA says--Bloomberg. Article | Follow @FiercePharma
> J&J should split itself three ways, Goldman analyst says. More
> Study of Treanda shows great promise for Teva's drug. News
> ASCO: Data on J&J, Medivation meds spell trouble for Provenge. Story
Medical Devices News
@MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce
> SentreHEART pulls in $26M for surgical suture device. Article
> Device investment firm gets support from Medtronic, Abbott. News
> LabCorp grabs Medtox for $241M. More
> Boston Sci gets FDA nod for new stent sizes. Story
Biotech IT News
> Proteins computer-designed to block flu invasions. Story
> Accelrys software to support efforts in Texas to study rare cancers. Article
> NIH group to award up to $20B in IT contracts. More
> Dotmatics starts up mobile strategy with iPad app. News
And Finally… This year's $500,000 Lemelson-MIT prize went to Stanford University's Stephen Quake, a founder of Helicos BioSciences, whose biotech inventions could lead to non-invasive prenatal tests for Down syndrome and other genetic diseases. Report